Sanofi (NASDAQ:SNY) Shares Bought by DCF Advisers LLC

DCF Advisers LLC boosted its position in shares of Sanofi (NASDAQ:SNY) by 31.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,500 shares of the company’s stock after buying an additional 3,500 shares during the period. DCF Advisers LLC’s holdings in Sanofi were worth $699,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. increased its holdings in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Sunbelt Securities Inc. increased its holdings in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. Sierra Ocean LLC acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $44,000. Finally, Versant Capital Management Inc acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Down 1.4 %

Sanofi stock opened at $57.79 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm has a market capitalization of $146.66 billion, a price-to-earnings ratio of 23.21, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The stock’s fifty day moving average is $54.39 and its two-hundred day moving average is $52.92.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.